Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

12.61USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$12.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
139,073
52-wk High
$27.06
52-wk Low
$3.61

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $117.83
Shares Outstanding(Mil.): 12.64
Dividend: --
Yield (%): --

Financials

  GLMD.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.22 -- --
ROI: -137.95 1.78 14.61
ROE: -140.43 3.29 16.33

BRIEF-Galmed Pharmaceuticals Q1 Loss Per Share $0.17

* GALMED PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Galmed Pharmaceuticals To Report First Quarter 2018 Financial Results And Provide Business Update On Wednesday, May 9

* GALMED PHARMACEUTICALS TO REPORT FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON WEDNESDAY, MAY 9 Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Galmed Pharmaceuticals Announces Pricing Of $6 Mln Registered Direct Offering

* ANNOUNCES PRICING OF $6.0 MILLION REGISTERED DIRECT OFFERING

03 Apr 2018

BRIEF-Galmed Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* GALMED PHARMACEUTICALS LTD FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text: [https://bit.ly/2G8U5GO] Further company coverage:

26 Mar 2018

Earnings vs. Estimates